Abstract: A raw material for forming a thin film, comprising a compound represented by General Formula (1) below. wherein R1 represents an isopropyl group, R2 represents a methyl group, R3 and R4 each independently represent a linear or branched alkyl group having 1 to 5 carbon atoms, A represents a propane-1,2-diyl group and M represents copper, nickel, cobalt or manganese.

Abstract: The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.

Abstract: The invention provides novel zwitterionic monomers and polymers (including copolymers) with pendent phosphonium-based zwitterionic moieties, and compositions and products comprising same, as well as related methods and uses of the compositions, for example, as surfactants, coatings, and interlayer materials, biomedical materials or agents.

Abstract: A method of preparing an ester by reacting a carboxylic acid with a (C1-C36)alcohol in the presence of a catalyst that is suitable for preparing carboxylic acid esters of monomeric carboxylic acids in high yield. The method reduces by-products of the reaction, in particular esters of dimeric, trimeric and/or oligomeric carboxylic acids. The method requires a minimal excess of alcohol and does not require removal of water and/or carboxylic acid ester from the reaction mixture. The method is particularly suitable for the reaction of hydroxyalkylcarboxylic acids and fatty alcohols.

Abstract: Compounds are provided that function as thyromimetics, which compounds have utility for treating diseases such as neurodegenerative disorders. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation. Such compounds have the structure of Formula (I) as shown herein, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof.

Abstract: Process for the production of methylidene malonates and cyanoacrylates employing in-situ formed iminium salts derived from acid halides and/or acid anhydrides and N,N,N?,N?-tetra hydrocarbyl diaminoalkanes, the acid halides and/or acid anhydrides being present in a molar excess relative to the diaminoalkanes, as co-reactants with select malonic acid esters and cyanoacetates, respectively.

Abstract: An embodiment relates to a substance comprising an end-capped amino compound comprising an amino compound and at least a portion of an end capping agent, wherein the at least the portion of the end capping agent contains no primary alkyl amine group and wherein the substance exhibits no activity as measured by: (a) a Cytotox CALUX assay; (b) a Steroidogenesis ER? CALUX assay; (c) a AR CALUX assay; (d) a Anti ERr? CALUX assay; (e) a Steroidogenesis AR CALUX assay; (f) an anti-AR CALUX assay; (g) a TR? CALUX assay; (h) a anti-TR? CALUX assay; (i) a TTR-TR? CALUX assay; or (j) a TPO assay.

Abstract: This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections such as HCV or HBV.

Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.

Abstract: The present invention relates to novel compounds containing fluorinated end groups, to the use thereof as surface-active substances, and to compositions comprising these compounds.

Abstract: A ligand includes a molecular skeleton, a first coordinating group connected to the molecular skeleton, at least one initial group connected to the molecular skeleton, and a protecting group connected to an end of each initial group away from the molecular skeleton. Each initial group is capable of forming a second coordinating group after deprotection.

Abstract: A process for preparing a 2-(1,2,2-trimethyl-3-cyclopentenyl)-2-oxoethyl carboxylate compound of the following general formula (6), wherein R represents a monovalent hydrocarbon group having 1 to 9 carbon atoms, the process comprising esterifying a 2-(1,2,2-trimethyl-3-cyclopentenyl)-2-oxoethyl compound of the following general formula (5), wherein X represents a hydroxyl group or a halogen atom, to form the 2-(1,2,2-trimethyl-3-cyclopentenyl)-2-oxoethyl carboxylate compound (6).

Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X1, X2, R1, R2, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

Abstract: The present invention concerns a composition suitable for working and shaping metals, in particular providing a lubricating effect, including polymers of the following formula: [R—O(—CH(CH3)—CH2O—)n(CH2—CH2O—)p—]1+xP(?O)(OH)2-x in which: R is a linear or branched, preferably linear, saturated or unsaturated hydrocarbon group, comprising between 8 and 12 carbon atoms; n is a number, which may or may not be an integer, between 6 and 20; p is a number, which may or may not be an integer, between 4 and 25; and x is a number between 0 and 1, and in particular between 0.1 and 0.9.

Abstract: Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate. Pharmaceutical compositions comprising the crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate are also disclosed.

Abstract: A compound with anti-drug resistant bacteria activity having the formula (I): (I) is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: The present invention relates to a new process for the preparation of the crystalline polymorph of sodium neridronate in form hemihydrate F, comprising the following steps: a) reacting the 6-aminohexanoic acid with a mixture of phosphorous acid and methanesulfonic acid at a temperature in the range from 60 to 80° C., under stirring, until a clear solution is obtained; b) adding phosphorus trichloride to said solution of step (a) under stirring at a temperature in the range of 60 to 80° C.; c) diluting with water the reaction mixture obtained from the previous step (b) and heating said water diluted mixture at a temperature in the range from 80 to 120° C.; d) cooling the heated mixture obtained in step (c) up to room temperature, diluting it with water, then slowly adding an aqueous sodium hydroxide solution up to a pH in the range from 4.2 to 4.6, to obtain a neutralized solution; e) bringing the neutralized solution of step (d) up to a temperature of about 70° C.

Abstract: This invention relates to a method for producing a high-purity cyclohexenone long-chain alcohol represented by formula I, and produces the compound of formula I by a metal-mediated Barbier reaction. The method of the present invention has advantages in its short scheme, high yield, and high-purity product, and is suitable for industrial scale up.

Abstract: The invention provides (meth)acrylic oligomers prepared from C1-C20 alkyl and C5-C20 cycloalkyl (meth)acrylates, wherein said oligomers have a Mn of about 300 g/mole to about 3,000 g/mole; a Mw of about 700 g/mole to about 6,000 g/mole; a Mz of about 900 g/mole to about 10,000 g/mole. The oligomers may have a Yellowness Index, according to ASTM E313 of less than 2. The oligomers of the invention are useful as tackifiers in adhesive compositions, but also are believed to be useful also in general polymer modification as plasticizers, leveling agents, viscosity reducers (i.e., rheology modifiers), and for increasing solids content in solvent-borne applications of all types with little detrimental impact on viscosity. The invention also provides adhesive compositions and laminate articles coated on at least one side with the adhesive compositions of the invention.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula is disclosed. A method of preparing the compound of formula (I) is also disclosed.